A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Two Sigma Advisers, LP holds 8,300 shares of PRTA stock, worth $171,312. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,300
Previous 146,800 94.35%
Holding current value
$171,312
Previous $5.33 Million 96.16%
% of portfolio
0.0%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$24.75 - $40.66 $3.43 Million - $5.63 Million
-138,500 Reduced 94.35%
8,300 $205,000
Q4 2023

Feb 14, 2024

SELL
$32.31 - $52.32 $1.84 Million - $2.98 Million
-57,000 Reduced 27.97%
146,800 $5.33 Million
Q3 2023

Nov 14, 2023

SELL
$47.3 - $70.6 $2.96 Million - $4.41 Million
-62,500 Reduced 23.47%
203,800 $9.83 Million
Q2 2023

Aug 14, 2023

SELL
$48.26 - $78.59 $5.55 Million - $9.04 Million
-115,000 Reduced 30.16%
266,300 $18.2 Million
Q1 2023

May 15, 2023

BUY
$46.97 - $58.27 $2.55 Million - $3.16 Million
54,300 Added 16.61%
381,300 $18.5 Million
Q4 2022

Feb 14, 2023

SELL
$52.05 - $65.0 $416,400 - $520,000
-8,000 Reduced 2.39%
327,000 $19.7 Million
Q3 2022

Nov 14, 2022

SELL
$25.16 - $60.63 $2.84 Million - $6.83 Million
-112,700 Reduced 25.17%
335,000 $20.3 Million
Q3 2022

Nov 14, 2022

SELL
$25.16 - $60.63 $2.84 Million - $6.83 Million
-112,700 Reduced 25.17%
335,000 $20.3 Million
Q2 2022

Aug 15, 2022

BUY
$22.73 - $39.98 $715,995 - $1.26 Million
31,500 Added 7.57%
447,700 $12.2 Million
Q1 2022

May 16, 2022

BUY
$30.27 - $49.22 $236,106 - $383,916
7,800 Added 1.91%
416,200 $15.2 Million
Q4 2021

Feb 14, 2022

SELL
$42.11 - $73.26 $2.75 Million - $4.78 Million
-65,300 Reduced 13.79%
408,400 $20.2 Million
Q3 2021

Nov 15, 2021

BUY
$48.2 - $78.89 $2.48 Million - $4.05 Million
51,400 Added 12.17%
473,700 $33.7 Million
Q2 2021

Aug 16, 2021

BUY
$21.63 - $57.65 $1.63 Million - $4.35 Million
75,500 Added 21.77%
422,300 $21.7 Million
Q1 2021

May 17, 2021

BUY
$11.0 - $28.24 $1.88 Million - $4.82 Million
170,600 Added 96.82%
346,800 $8.71 Million
Q4 2020

Feb 16, 2021

SELL
$10.12 - $13.94 $358,248 - $493,476
-35,400 Reduced 16.73%
176,200 $2.12 Million
Q3 2020

Nov 16, 2020

SELL
$9.93 - $13.47 $31,776 - $43,104
-3,200 Reduced 1.49%
211,600 $2.11 Million
Q2 2020

Aug 14, 2020

BUY
$9.56 - $12.51 $104,204 - $136,359
10,900 Added 5.35%
214,800 $2.25 Million
Q1 2020

May 15, 2020

BUY
$7.54 - $15.77 $21,112 - $44,156
2,800 Added 1.39%
203,900 $2.18 Million
Q4 2019

Feb 14, 2020

SELL
$7.48 - $17.01 $146,608 - $333,396
-19,600 Reduced 8.88%
201,100 $3.18 Million
Q3 2019

Nov 14, 2019

SELL
$6.89 - $10.45 $377,572 - $572,660
-54,800 Reduced 19.89%
220,700 $1.73 Million
Q2 2019

Aug 14, 2019

SELL
$8.85 - $12.49 $38,940 - $54,956
-4,400 Reduced 1.57%
275,500 $2.91 Million
Q1 2019

May 15, 2019

BUY
$10.32 - $14.49 $1.47 Million - $2.06 Million
142,200 Added 103.27%
279,900 $3.4 Million
Q4 2018

Feb 14, 2019

BUY
$8.73 - $13.74 $660,861 - $1.04 Million
75,700 Added 122.1%
137,700 $1.42 Million
Q3 2018

Nov 14, 2018

BUY
$12.7 - $15.79 $617,220 - $767,394
48,600 Added 362.69%
62,000 $811,000
Q2 2018

Aug 14, 2018

BUY
$10.99 - $44.21 $147,266 - $592,414
13,400 New
13,400 $195,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $968M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.